Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation.

Gunst JD, Kjær K, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virus Erad. 2019 Sep 18;5(3):133-137.

PMID:
31700656
2.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation.

Gunst JD, Kjær K, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virus Erad. 2019 Sep 18;5(3):133-137.

PMID:
31700655
3.

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues.

Denton PW, Søgaard OS, Tolstrup M.

Front Microbiol. 2019 Aug 21;10:1956. doi: 10.3389/fmicb.2019.01956. eCollection 2019. Review.

4.

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

Schleimann MH, Kobberø ML, Vibholm LK, Kjær K, Giron LB, Busman-Sahay K, Chan CN, Nekorchuk M, Schmidt M, Wittig B, Damsgaard TE, Ahlburg P, Hellfritzsch MB, Zuwala K, Rothemejer FH, Olesen R, Schommers P, Klein F, Dweep H, Kossenkov A, Nyengaard JR, Estes JD, Abdel-Mohsen M, Østergaard L, Tolstrup M, Søgaard OS, Denton PW.

EBioMedicine. 2019 Jul;45:328-340. doi: 10.1016/j.ebiom.2019.07.005. Epub 2019 Jul 9.

5.

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.

AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213.

PMID:
30932955
6.

cAIMP administration in humanized mice induces a chimerization-level-dependent STING response.

Andersen AHF, Olesen R, Jønsson KL, Højen JF, Krapp C, Mack K, Thomsen MK, Østergaard L, Tolstrup M, Dagnaes-Hansen F, Jakobsen MR, Denton PW.

Immunology. 2019 Jun;157(2):163-172. doi: 10.1111/imm.13061. Epub 2019 May 6.

PMID:
30919991
7.

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.

Vibholm LK, Lorenzi JCC, Pai JA, Cohen YZ, Oliveira TY, Barton JP, Garcia Noceda M, Lu CL, Ablanedo-Terrazas Y, Del Rio Estrada PM, Reyes-Teran G, Tolstrup M, Denton PW, Damsgaard T, Søgaard OS, Nussenzweig MC.

J Virol. 2019 Apr 3;93(8). pii: e01920-18. doi: 10.1128/JVI.01920-18. Print 2019 Apr 15.

8.

Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs.

Frich CK, Krüger F, Walther R, Domar C, Andersen AHF, Tvilum A, Dagnæs-Hansen F, Denton PW, Tolstrup M, Paludan SR, Münch J, Zelikin AN.

J Control Release. 2019 Jan 28;294:298-310. doi: 10.1016/j.jconrel.2018.12.016. Epub 2018 Dec 12.

PMID:
30552954
9.

Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function.

Laustsen A, Bak RO, Krapp C, Kjær L, Egedahl JH, Petersen CC, Pillai S, Tang HQ, Uldbjerg N, Porteus M, Roan NR, Nyegaard M, Denton PW, Jakobsen MR.

Nat Commun. 2018 Aug 30;9(1):3525. doi: 10.1038/s41467-018-05816-y.

10.

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.

Winckelmann A, Morcilla V, Shao W, Schleimann MH, Hojen JF, Schlub TE, Denton PW, Østergaard L, Søgaard OS, Tolstrup M, Palmer S.

AIDS. 2018 Aug 24;32(13):1793-1802. doi: 10.1097/QAD.0000000000001861.

11.

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.

Brinkmann CR, Højen JF, Rasmussen TA, Kjær AS, Olesen R, Denton PW, Østergaard L, Ouyang Z, Lichterfeld M, Yu X, Søgaard OS, Dinarello C, Tolstrup M.

mSphere. 2018 Feb 14;3(1). pii: e00616-17. doi: 10.1128/mSphere.00616-17. eCollection 2018 Jan-Feb.

12.

Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection.

Schleimann MH, Leth S, Krarup AR, Mortensen J, Barstad B, Zaccarin M, Denton PW, Mohey R.

Open Forum Infect Dis. 2018 Jan 9;5(2):ofy006. doi: 10.1093/ofid/ofy006. eCollection 2018 Feb.

13.

The role of miR-29a in HIV-1 replication and latency.

Frattari G, Aagaard L, Denton PW.

J Virus Erad. 2017 Oct 1;3(4):185-191.

14.

Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma.

Vase MØ, Ludvigsen M, Bendix K, Dutoit SH, Hjortebjerg R, Petruskevicius I, Møller MB, Pedersen G, Denton PW, Honoré B, Rabinovich GA, Larsen CS, d'Amore F.

AIDS. 2017 Oct 23;31(16):2311-2313. doi: 10.1097/QAD.0000000000001622. No abstract available.

PMID:
28991028
15.

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A, Keshavarzian A, Deng X, Olesen R, Petersen AM, Benfield T, Østergaard L, Rasmussen TA, Agnholt J, Nyengaard JR, Landay A, Søgaard OS, Pillai SK, Tolstrup M, Denton PW.

Mucosal Immunol. 2018 Mar;11(2):449-461. doi: 10.1038/mi.2017.59. Epub 2017 Aug 2.

16.

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Vibholm L, Schleimann MH, Højen JF, Benfield T, Offersen R, Rasmussen K, Olesen R, Dige A, Agnholt J, Grau J, Buzon M, Wittig B, Lichterfeld M, Petersen AM, Deng X, Abdel-Mohsen M, Pillai SK, Rutsaert S, Trypsteen W, De Spiegelaere W, Vandekerchove L, Østergaard L, Rasmussen TA, Denton PW, Tolstrup M, Søgaard OS.

Clin Infect Dis. 2017 Jun 15;64(12):1686-1695. doi: 10.1093/cid/cix201.

17.

Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Wahl A, Ho PT, Denton PW, Garrett KL, Hudgens MG, Swartz G, O'Neill C, Veronese F, Kashuba AD, Garcia JV.

Sci Rep. 2017 Feb 1;7:41098. doi: 10.1038/srep41098.

18.

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

Leth S, Schleimann MH, Nissen SK, Højen JF, Olesen R, Graversen ME, Jørgensen S, Kjær AS, Denton PW, Mørk A, Sommerfelt MA, Krogsgaard K, Østergaard L, Rasmussen TA, Tolstrup M, Søgaard OS.

Lancet HIV. 2016 Oct;3(10):e463-72. doi: 10.1016/S2352-3018(16)30055-8. Epub 2016 Jul 7.

PMID:
27658863
19.

Broad activation of latent HIV-1 in vivo.

Barton K, Hiener B, Winckelmann A, Rasmussen TA, Shao W, Byth K, Lanfear R, Solomon A, McMahon J, Harrington S, Buzon M, Lichterfeld M, Denton PW, Olesen R, Østergaard L, Tolstrup M, Lewin SR, Søgaard OS, Palmer S.

Nat Commun. 2016 Sep 8;7:12731. doi: 10.1038/ncomms12731.

20.

Immune checkpoints and the HIV-1 reservoir: proceed with caution.

Olesen R, Leth S, Nymann R, Østergaard L, Søgaard OS, Denton PW, Tolstrup M.

J Virus Erad. 2016 Jul 1;2(3):183-6. No abstract available.

21.

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.

Offersen R, Nissen SK, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virol. 2016 Apr 14;90(9):4441-4453. doi: 10.1128/JVI.00222-16. Print 2016 May.

22.

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.

Denton PW, Søgaard OS, Tolstrup M.

J Transl Med. 2016 Feb 9;14:44. doi: 10.1186/s12967-016-0807-y. Review.

23.

ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Olesen R, Swanson MD, Kovarova M, Nochi T, Chateau M, Honeycutt JB, Long JM, Denton PW, Hudgens MG, Richardson A, Tolstrup M, Østergaard L, Wahl A, Garcia JV.

J Clin Invest. 2016 Mar 1;126(3):892-904. doi: 10.1172/JCI64212. Epub 2016 Feb 8.

24.

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.

Bjerg Christensen A, Dige A, Vad-Nielsen J, Brinkmann CR, Bendix M, Østergaard L, Tolstrup M, Søgaard OS, Rasmussen TA, Randel Nyengaard J, Agnholt J, Denton PW.

Mediators Inflamm. 2015;2015:120605. doi: 10.1155/2015/120605. Epub 2015 Dec 1.

25.

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.

Leth S, Nymann R, Jørgensen S, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.

AIDS. 2016 Mar 13;30(5):713-21. doi: 10.1097/QAD.0000000000000974.

PMID:
26595541
26.

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard L, Tolstrup M.

PLoS Pathog. 2015 Sep 17;11(9):e1005142. doi: 10.1371/journal.ppat.1005142. eCollection 2015 Sep.

27.

Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.

Jønsson KL, Tolstrup M, Vad-Nielsen J, Kjær K, Laustsen A, Andersen MN, Rasmussen TA, Søgaard OS, Østergaard L, Denton PW, Jakobsen MR.

Antimicrob Agents Chemother. 2015 Jul;59(7):3984-94. doi: 10.1128/AAC.00574-15. Epub 2015 Apr 20.

28.

Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.

Martinez-Torres F, Nochi T, Wahl A, Garcia JV, Denton PW.

PLoS One. 2014 Oct 1;9(10):e108663. doi: 10.1371/journal.pone.0108663. eCollection 2014.

29.

Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV.

PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9.

30.

In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.

Watkins RL, Zou W, Denton PW, Krisko JF, Foster JL, Garcia JV.

Retrovirology. 2013 Oct 30;10:125. doi: 10.1186/1742-4690-10-125.

31.

Cryptopatches are essential for the development of human GALT.

Nochi T, Denton PW, Wahl A, Garcia JV.

Cell Rep. 2013 Jun 27;3(6):1874-84. doi: 10.1016/j.celrep.2013.05.037. Epub 2013 Jun 20.

32.

Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV.

PLoS One. 2013;8(3):e60024. doi: 10.1371/journal.pone.0060024. Epub 2013 Mar 20.

33.

Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice.

Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, Chateau M, Garcia JV.

PLoS Pathog. 2012;8(6):e1002732. doi: 10.1371/journal.ppat.1002732. Epub 2012 Jun 14.

34.

Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.

Zou W, Denton PW, Watkins RL, Krisko JF, Nochi T, Foster JL, Garcia JV.

Retrovirology. 2012 May 28;9:44. doi: 10.1186/1742-4690-9-44.

35.

IL-2 receptor γ-chain molecule is critical for intestinal T-cell reconstitution in humanized mice.

Denton PW, Nochi T, Lim A, Krisko JF, Martinez-Torres F, Choudhary SK, Wahl A, Olesen R, Zou W, Di Santo JP, Margolis DM, Garcia JV.

Mucosal Immunol. 2012 Sep;5(5):555-66. doi: 10.1038/mi.2012.31. Epub 2012 May 9.

36.

Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.

Denton PW, Garcia JV.

Trends Microbiol. 2012 Jun;20(6):268-74. doi: 10.1016/j.tim.2012.03.007. Epub 2012 Apr 12. Review.

37.

Generation of HIV latency in humanized BLT mice.

Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, Chateau M, Nochi T, Krisko JF, Spagnuolo RA, Margolis DM, Garcia JV.

J Virol. 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11. Epub 2011 Oct 19.

38.

Humanized mouse models of HIV infection.

Denton PW, García JV.

AIDS Rev. 2011 Jul-Sep;13(3):135-48. Review.

39.

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV.

J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18.

40.

Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.

Olesen R, Wahl A, Denton PW, Garcia JV.

J Reprod Immunol. 2011 Mar;88(2):195-203. doi: 10.1016/j.jri.2010.11.005. Epub 2011 Jan 21. Review.

41.

Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.

Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, Zou W, Payne DA, Estes JD, Garcia JV.

PLoS One. 2010 Jan 21;5(1):e8829. doi: 10.1371/journal.pone.0008829.

42.

Novel humanized murine models for HIV research.

Denton PW, Garcia JV.

Curr HIV/AIDS Rep. 2009 Feb;6(1):13-9. Review.

43.

Functional and phenotypic characterization of the humanized BLT mouse model.

Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV.

Curr Top Microbiol Immunol. 2008;324:149-65. Review.

PMID:
18481459
44.

Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.

Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV.

PLoS Med. 2008 Jan 15;5(1):e16. doi: 10.1371/journal.pmed.0050016.

45.

Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.

Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, Melkus MW, Padgett-Thomas A, Zupancic M, Haase AT, Garcia JV.

J Exp Med. 2007 Apr 16;204(4):705-14. Epub 2007 Mar 26.

46.

Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AK, Haase AT, Garcia JV.

Nat Med. 2006 Nov;12(11):1316-22. Epub 2006 Oct 22.

PMID:
17057712
47.

Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.

Wei BL, Denton PW, O'Neill E, Luo T, Foster JL, Garcia JV.

J Virol. 2005 May;79(9):5705-12.

48.

Supplemental Content

Loading ...
Support Center